We are seeking new patients for an ongoing clinical trial of a new, first in class, oral cholesterol medication called Bempedoic acid. Bempedoic acid is being studied to assess the reduction in risk of major adverse cardiovascular events in patients who are unable to take and/or tolerate cholesterol lowering “statin” medications.
Bempedoic acid lowers LDL cholesterol (bad cholesterol). It is not a “statin” medication.
To qualify, patients must be statin intolerant—meaning patients must be unable take statin medications to lower cholesterol. (Patients who are on very low doses of statin drugs may still qualify for this trial). The study will last for approximately 2-4 years. All medications, products, exams, and services associated with the study are provided free of charge to those who qualify. Study participants will be paid for each completed visit.
If you are statin intolerant and interested in participating in this research study, please contact one of the research coordinators at 319-272-2530 to learn more and see if you qualify.
Samantha Beenken, BSN, RN: firstname.lastname@example.org
Karrie Cheeseman, BSN, RN: email@example.com
Jessica Schwake, BSN, RN: firstname.lastname@example.org